CA2891365A1 - Composition for immediate and extended release - Google Patents

Composition for immediate and extended release Download PDF

Info

Publication number
CA2891365A1
CA2891365A1 CA2891365A CA2891365A CA2891365A1 CA 2891365 A1 CA2891365 A1 CA 2891365A1 CA 2891365 A CA2891365 A CA 2891365A CA 2891365 A CA2891365 A CA 2891365A CA 2891365 A1 CA2891365 A1 CA 2891365A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
composition according
tolterodine
active ingredient
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2891365A
Other languages
English (en)
French (fr)
Inventor
Varinder Ahuja
Rajan Verma
Umesh Vinayakrao Barabde
Arne HAGSTEN
Kristin Wannerberger
Rambabu BOORUGU
Amol Vilasrao SOMWANSHI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring BV filed Critical Ferring BV
Publication of CA2891365A1 publication Critical patent/CA2891365A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2891365A 2012-11-21 2013-11-21 Composition for immediate and extended release Abandoned CA2891365A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN3575DE2012 2012-11-21
IN3575/DEL/2012 2012-11-21
IN3947DE2012 2012-12-20
IN3947/DEL/2012 2012-12-20
PCT/EP2013/074373 WO2014079922A1 (en) 2012-11-21 2013-11-21 Composition for immediate and extended release

Publications (1)

Publication Number Publication Date
CA2891365A1 true CA2891365A1 (en) 2014-05-30

Family

ID=49619947

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2891365A Abandoned CA2891365A1 (en) 2012-11-21 2013-11-21 Composition for immediate and extended release

Country Status (18)

Country Link
EP (1) EP2922525A1 (enrdf_load_stackoverflow)
JP (1) JP2016500088A (enrdf_load_stackoverflow)
KR (1) KR20150085826A (enrdf_load_stackoverflow)
CN (1) CN104797240A (enrdf_load_stackoverflow)
AR (1) AR093585A1 (enrdf_load_stackoverflow)
AU (1) AU2013349682A1 (enrdf_load_stackoverflow)
BR (1) BR112015011430A2 (enrdf_load_stackoverflow)
CA (1) CA2891365A1 (enrdf_load_stackoverflow)
EA (1) EA201590805A1 (enrdf_load_stackoverflow)
HK (1) HK1213779A1 (enrdf_load_stackoverflow)
IL (1) IL238648A0 (enrdf_load_stackoverflow)
IN (1) IN2015DN03984A (enrdf_load_stackoverflow)
MX (1) MX2015006399A (enrdf_load_stackoverflow)
PH (1) PH12015501096A1 (enrdf_load_stackoverflow)
SG (2) SG11201503913TA (enrdf_load_stackoverflow)
TW (1) TW201422254A (enrdf_load_stackoverflow)
WO (1) WO2014079922A1 (enrdf_load_stackoverflow)
ZA (1) ZA201503603B (enrdf_load_stackoverflow)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12389928B1 (en) * 2024-10-25 2025-08-19 Mccormick & Company, Inc. Flavor-changing product

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210103589A (ko) 2013-07-23 2021-08-23 세레니티 파마슈티컬즈 엘엘씨 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물
KR20150144209A (ko) * 2014-06-16 2015-12-24 훼링 비.브이. 안정화된 데스모프레신 또는 이의 약학적으로 허용가능한 염을 함유 약학 조성물
WO2016081772A1 (en) * 2014-11-20 2016-05-26 Allergan, Inc. Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist
BR112017014953A2 (pt) 2015-01-12 2018-03-13 Nano Pharmaceutical Laboratories Llc microglóbulos de liberação controlada em camadas e métodos para produção dos mesmos
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
EP3344240A4 (en) * 2015-09-01 2019-09-04 Wellesley Pharmaceuticals, LLC FORMULATION WITH EXTENDED, DELAYED AND IMMEDIATE RELEASE, METHOD FOR THE PRODUCTION AND USE THEREOF
AU2016331871A1 (en) * 2015-09-30 2018-05-17 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
CN108430465A (zh) * 2015-09-30 2018-08-21 韦尔斯利医药有限公司 用于缓解尿频的组合物、其制造方法和用途
TW201726114A (zh) * 2015-11-23 2017-08-01 魏斯理製藥公司 降低排尿頻率之組成物、其製備方法、及其應用
CA3008628A1 (en) * 2015-12-18 2017-06-22 Wellesley Pharmaceuticals, Llc Composition for reducing frequency of urination, method of making and use thereof
CA3018285C (en) 2016-04-21 2024-02-27 Valcuria Ab Composition and method for pretreating cancer
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CA3046725A1 (en) * 2017-01-11 2018-07-19 Ferring B.V. A fast disintegrating pharmaceutical composition
WO2019039836A2 (ko) * 2017-08-22 2019-02-28 아주대학교산학협력단 퇴행성 신경질환 치료용 복합 제형 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003184A1 (en) 1996-07-19 1998-01-29 Clarke-Garegg, Margaret, A. Levan derivatives, their preparation, composition and applications including medical and food applications
SE9803871D0 (sv) 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
DE60307082T4 (de) * 2002-05-07 2015-04-30 Ferring B.V. In der mundhöhle dispergierbare phamarzeutische zusammensetzung mit desmopressin
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
CN100366294C (zh) 2004-04-30 2008-02-06 量子高科(北京)研究院有限公司 一种口腔速溶制剂及其生产方法
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
WO2007029087A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Controlled release multiple unit formulations
US20090192228A1 (en) 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
KR20110075011A (ko) * 2008-11-10 2011-07-05 (주)아모레퍼시픽 서방성 미립자 및 이의 제조방법
US9078830B2 (en) * 2009-07-31 2015-07-14 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
RU2566269C2 (ru) 2010-03-29 2015-10-20 Ферринг Б.В. Быстрорастворимая фармацевтическая композиция
MX356601B (es) * 2010-03-30 2018-05-29 Productos Maver S A De C V Combinación farmacéutica con efecto antimigrañoso, en presentación sólida de liberación diferenciada.
US20120135050A1 (en) * 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12389928B1 (en) * 2024-10-25 2025-08-19 Mccormick & Company, Inc. Flavor-changing product

Also Published As

Publication number Publication date
EA201590805A1 (ru) 2015-11-30
ZA201503603B (en) 2016-01-27
EP2922525A1 (en) 2015-09-30
CN104797240A (zh) 2015-07-22
JP2016500088A (ja) 2016-01-07
PH12015501096A1 (en) 2015-07-27
AU2013349682A1 (en) 2015-06-04
IL238648A0 (en) 2015-06-30
BR112015011430A2 (pt) 2017-07-11
TW201422254A (zh) 2014-06-16
IN2015DN03984A (enrdf_load_stackoverflow) 2015-10-02
WO2014079922A1 (en) 2014-05-30
SG10201703388TA (en) 2017-05-30
MX2015006399A (es) 2015-07-21
SG11201503913TA (en) 2015-06-29
KR20150085826A (ko) 2015-07-24
HK1213779A1 (zh) 2016-07-15
AR093585A1 (es) 2015-06-10

Similar Documents

Publication Publication Date Title
CA2891365A1 (en) Composition for immediate and extended release
US20150306170A1 (en) Composition for immediate and extended release
US10512695B2 (en) Fast dissolving pharmaceutical composition
TWI537010B (zh) 快速溶解的藥學組成物
US10023335B2 (en) Fast dissolving pharmaceutical composition
US10952959B2 (en) Fast disintegrating pharmaceutical composition
HK1181649B (en) A fast dissolving pharmaceutical composition

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20191121